Group 1: Company Performance - Eli Lilly has emerged as a leader in the GLP-1 drug category, particularly with its medication tirzepatide, which effectively lowers blood sugar and promotes weight loss [1] - Tirzepatide became the best-selling drug globally last year, surpassing Merck's Keytruda, and is marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss [2] - Sales of tirzepatide have driven Eli Lilly's stock price up by 400% over the past five years, although the stock has seen a decline of about 4% in 2026 [2] Group 2: Recent Acquisitions and Developments - Eli Lilly announced the acquisition of Orna Therapeutics for $2.4 billion, which is developing innovative gene therapies using circular RNA technology [3] - Orna's therapy, ORN-252, aims to enable the patient's body to generate necessary changes to combat diseases, representing a shift from traditional lab-modified treatments [4] - The new therapy is described as "clinical trial-ready," but commercial sales may still be several years away due to the lengthy drug development process [5] Group 3: Pipeline Expansion - In addition to the Orna acquisition, Eli Lilly is actively expanding its pipeline, including a $350 million collaboration with a Chinese biotech firm for immune disorder and cancer treatments [6] - The company also announced a billion-dollar deal with a German firm to develop gene therapies for hearing loss [6]